AAPL294.38+5.02 (+1.73%) ▲|ABBV251.06-0.58 (-0.23%) ▼|ABT92.18+1.44 (+1.59%) ▲|ACN131.13+6.69 (+5.38%) ▲|ADBE210.98+5.96 (+2.91%) ▲|AMAT650.91-72.09 (-9.97%) ▼|AMD540.88-40.03 (-6.89%) ▼|AMGN361.33-0.79 (-0.22%) ▼|AMT166.08+2.51 (+1.53%) ▲|AMZN241.70+3.36 (+1.41%) ▲|AVGO369.34-8.41 (-2.23%) ▼|AXP348.00+9.75 (+2.88%) ▲|BA218.58+2.11 (+0.97%) ▲|BAC58.36+1.38 (+2.42%) ▲|BKNG182.64+4.40 (+2.47%) ▲|BLK980.38+18.82 (+1.96%) ▲|BMY56.44-1.18 (-2.05%) ▼|BNY146.02+1.41 (+0.98%) ▲|BRK-B499.74-0.65 (-0.13%) ▼|C140.13+0.17 (+0.12%) ▲|CAT991.41-73.49 (-6.90%) ▼|CL92.76+1.08 (+1.18%) ▲|CMCSA23.73-0.82 (-3.34%) ▼|COF204.82+4.20 (+2.09%) ▲|COP103.22-0.74 (-0.71%) ▼|COST924.67-10.80 (-1.15%) ▼|CRM163.23+6.57 (+4.19%) ▲|CSCO117.01-0.45 (-0.38%) ▼|CVS104.81+1.36 (+1.31%) ▲|CVX165.69-0.07 (-0.04%) ▼|DE627.63-6.70 (-1.06%) ▼|DHR193.72+3.24 (+1.70%) ▲|DIS95.71-0.54 (-0.56%) ▼|DUK125.77-0.81 (-0.64%) ▼|EMR139.52-3.63 (-2.54%) ▼|FDX313.89+0.76 (+0.24%) ▲|GD362.86+8.62 (+2.43%) ▲|GE374.94+1.21 (+0.32%) ▲|GEV1,134.35-40.51 (-3.45%) ▼|GILD125.97-0.37 (-0.29%) ▼|GM75.52-1.56 (-2.02%) ▼|GOOG357.89+4.56 (+1.29%) ▲|GOOGL361.21+3.84 (+1.07%) ▲|GS1,019.61+8.24 (+0.81%) ▲|HD350.84-1.84 (-0.52%) ▼|HON221.75-2.15 (-0.96%) ▼|IBM286.25+5.04 (+1.79%) ▲|INTC127.02-12.61 (-9.03%) ▼|INTU267.08+6.08 (+2.33%) ▲|ISRG402.38+4.70 (+1.18%) ▲|JNJ253.98+0.01 (+0.00%) ▲|JPM334.07+6.74 (+2.06%) ▲|KO81.29+0.02 (+0.02%) ▲|LIN533.55+14.61 (+2.82%) ▲|LLY1,191.74-7.69 (-0.64%) ▼|LMT521.82+12.36 (+2.43%) ▲|LOW221.92+1.43 (+0.65%) ▲|LRCX391.26-42.07 (-9.71%) ▼|MA522.44+8.84 (+1.72%) ▲|MCD269.43-0.88 (-0.33%) ▼|MDLZ59.35+1.51 (+2.61%) ▲|MDT79.20+0.97 (+1.24%) ▲|META612.91+49.62 (+8.81%) ▲|MMM159.96-1.95 (-1.20%) ▼|MO71.54-0.41 (-0.57%) ▼|MRK125.37-3.13 (-2.44%) ▼|MS211.86+2.82 (+1.35%) ▲|MSFT384.28+11.26 (+3.02%) ▲|MU1,032.28-122.01 (-10.57%) ▼|NEE86.37-1.40 (-1.60%) ▼|NFLX74.19+2.79 (+3.91%) ▲|NKE43.06+2.01 (+4.90%) ▲|NOW105.80+6.52 (+6.57%) ▲|NVDA197.58-2.51 (-1.25%) ▼|ORCL142.50-4.05 (-2.76%) ▼|PEP141.16+5.76 (+4.25%) ▲|PFE23.88-0.20 (-0.83%) ▼|PG147.43+0.79 (+0.54%) ▲|PLTR125.73+9.06 (+7.77%) ▲|PM177.69-3.22 (-1.78%) ▼|QCOM181.92-2.87 (-1.55%) ▼|RTX191.78+2.05 (+1.08%) ▲|SBUX103.39+1.20 (+1.17%) ▲|SCHW95.78+3.51 (+3.80%) ▲|SO95.12-0.59 (-0.62%) ▼|SPG223.00-0.65 (-0.29%) ▼|T20.48-0.22 (-1.06%) ▼|TMO513.33+11.97 (+2.39%) ▲|TMUS173.06+5.33 (+3.18%) ▲|TSLA425.30+4.70 (+1.12%) ▲|TXN298.41+0.34 (+0.11%) ▲|UBER72.66+0.50 (+0.69%) ▲|UNH426.54+10.91 (+2.62%) ▲|UNP277.73+5.73 (+2.11%) ▲|UPS109.54+2.04 (+1.90%) ▲|USB61.96+1.56 (+2.58%) ▲|V351.08+7.99 (+2.33%) ▲|VZ41.99-0.35 (-0.83%) ▼|WFC85.94+3.30 (+3.99%) ▲|WMT108.82-4.44 (-3.92%) ▼|XOM136.28-0.44 (-0.32%) ▼|AAPL294.38+5.02 (+1.73%) ▲|ABBV251.06-0.58 (-0.23%) ▼|ABT92.18+1.44 (+1.59%) ▲|ACN131.13+6.69 (+5.38%) ▲|ADBE210.98+5.96 (+2.91%) ▲|AMAT650.91-72.09 (-9.97%) ▼|AMD540.88-40.03 (-6.89%) ▼|AMGN361.33-0.79 (-0.22%) ▼|AMT166.08+2.51 (+1.53%) ▲|AMZN241.70+3.36 (+1.41%) ▲|AVGO369.34-8.41 (-2.23%) ▼|AXP348.00+9.75 (+2.88%) ▲|BA218.58+2.11 (+0.97%) ▲|BAC58.36+1.38 (+2.42%) ▲|BKNG182.64+4.40 (+2.47%) ▲|BLK980.38+18.82 (+1.96%) ▲|BMY56.44-1.18 (-2.05%) ▼|BNY146.02+1.41 (+0.98%) ▲|BRK-B499.74-0.65 (-0.13%) ▼|C140.13+0.17 (+0.12%) ▲|CAT991.41-73.49 (-6.90%) ▼|CL92.76+1.08 (+1.18%) ▲|CMCSA23.73-0.82 (-3.34%) ▼|COF204.82+4.20 (+2.09%) ▲|COP103.22-0.74 (-0.71%) ▼|COST924.67-10.80 (-1.15%) ▼|CRM163.23+6.57 (+4.19%) ▲|CSCO117.01-0.45 (-0.38%) ▼|CVS104.81+1.36 (+1.31%) ▲|CVX165.69-0.07 (-0.04%) ▼|DE627.63-6.70 (-1.06%) ▼|DHR193.72+3.24 (+1.70%) ▲|DIS95.71-0.54 (-0.56%) ▼|DUK125.77-0.81 (-0.64%) ▼|EMR139.52-3.63 (-2.54%) ▼|FDX313.89+0.76 (+0.24%) ▲|GD362.86+8.62 (+2.43%) ▲|GE374.94+1.21 (+0.32%) ▲|GEV1,134.35-40.51 (-3.45%) ▼|GILD125.97-0.37 (-0.29%) ▼|GM75.52-1.56 (-2.02%) ▼|GOOG357.89+4.56 (+1.29%) ▲|GOOGL361.21+3.84 (+1.07%) ▲|GS1,019.61+8.24 (+0.81%) ▲|HD350.84-1.84 (-0.52%) ▼|HON221.75-2.15 (-0.96%) ▼|IBM286.25+5.04 (+1.79%) ▲|INTC127.02-12.61 (-9.03%) ▼|INTU267.08+6.08 (+2.33%) ▲|ISRG402.38+4.70 (+1.18%) ▲|JNJ253.98+0.01 (+0.00%) ▲|JPM334.07+6.74 (+2.06%) ▲|KO81.29+0.02 (+0.02%) ▲|LIN533.55+14.61 (+2.82%) ▲|LLY1,191.74-7.69 (-0.64%) ▼|LMT521.82+12.36 (+2.43%) ▲|LOW221.92+1.43 (+0.65%) ▲|LRCX391.26-42.07 (-9.71%) ▼|MA522.44+8.84 (+1.72%) ▲|MCD269.43-0.88 (-0.33%) ▼|MDLZ59.35+1.51 (+2.61%) ▲|MDT79.20+0.97 (+1.24%) ▲|META612.91+49.62 (+8.81%) ▲|MMM159.96-1.95 (-1.20%) ▼|MO71.54-0.41 (-0.57%) ▼|MRK125.37-3.13 (-2.44%) ▼|MS211.86+2.82 (+1.35%) ▲|MSFT384.28+11.26 (+3.02%) ▲|MU1,032.28-122.01 (-10.57%) ▼|NEE86.37-1.40 (-1.60%) ▼|NFLX74.19+2.79 (+3.91%) ▲|NKE43.06+2.01 (+4.90%) ▲|NOW105.80+6.52 (+6.57%) ▲|NVDA197.58-2.51 (-1.25%) ▼|ORCL142.50-4.05 (-2.76%) ▼|PEP141.16+5.76 (+4.25%) ▲|PFE23.88-0.20 (-0.83%) ▼|PG147.43+0.79 (+0.54%) ▲|PLTR125.73+9.06 (+7.77%) ▲|PM177.69-3.22 (-1.78%) ▼|QCOM181.92-2.87 (-1.55%) ▼|RTX191.78+2.05 (+1.08%) ▲|SBUX103.39+1.20 (+1.17%) ▲|SCHW95.78+3.51 (+3.80%) ▲|SO95.12-0.59 (-0.62%) ▼|SPG223.00-0.65 (-0.29%) ▼|T20.48-0.22 (-1.06%) ▼|TMO513.33+11.97 (+2.39%) ▲|TMUS173.06+5.33 (+3.18%) ▲|TSLA425.30+4.70 (+1.12%) ▲|TXN298.41+0.34 (+0.11%) ▲|UBER72.66+0.50 (+0.69%) ▲|UNH426.54+10.91 (+2.62%) ▲|UNP277.73+5.73 (+2.11%) ▲|UPS109.54+2.04 (+1.90%) ▲|USB61.96+1.56 (+2.58%) ▲|V351.08+7.99 (+2.33%) ▲|VZ41.99-0.35 (-0.83%) ▼|WFC85.94+3.30 (+3.99%) ▲|WMT108.82-4.44 (-3.92%) ▼|XOM136.28-0.44 (-0.32%) ▼|
28.6 C
New York
Thursday, July 2, 2026

Tag: patients

WALL STREET RAISES RECORD BREAKING $4.2 MILLION AT 15TH ANNUAL LEVERAGED FINANCE FIGHTS MELANOMA BENEFIT SUPPORTING THE MELANOMA RESEARCH ALLIANCE

NEW YORK, June 13, 2025 /PRNewswire/ -- More than 1,100 private equity leaders, financiers and attorneys packed the Museum of Modern Art on June...

RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split

SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (the “Company”), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that a 1-for-8 reverse stock split of its outstanding shares of common stock will be effective at 11:59 pm Eastern Time June 16, 2025.

Connect Biopharma Presents Data Supporting Rademikibart at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress

– Rademikibart significantly improved lung function and asthma control in patients with eosinophilic-driven type 2 asthma –

Neurophet Participates in BIO USA 2025: To showcase Brain Imaging Analysis Solutions Including ‘Neurophet AQUA AD’

Highlight brain imaging analysis solutions, including 'Neurophet AQUA AD', which monitors side effects from Alzheimer's disease treatmentsTo accelerate partnering efforts with global pharmaceutical companies...

InspireMD Announces CE Mark Approval for CGuard® Prime Embolic Prevention System (EPS) Under European MDR for the Prevention of Stroke

MIAMI, June 13, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the company has received CE Mark approval under the European Medical Device Regulation (MDR) for the CGuard® Prime EPS.

Leading Independent Proxy Advisor Glass Lewis Recommends Shareholders Vote the GREEN proxy FOR ALL MediPharm Director Nominees

Independent proxy advisor Glass Lewis recommends that MediPharm shareholders vote for all of the Company's director nominees.

Hydration Room Expands to Rancho Cucamonga with New Wellness Clinic Focused on Proactive, Personalized Care

RANCHO CUCAMONGA, Calif., June 13, 2025 /PRNewswire/ -- Hydration Room, a leader in medically guided IV therapy and proactive wellness treatments, proudly announces the opening...

Fondazione Ricerca e Innovazione Cardiovascolare Completes Enrollment in TRANSFORM II RCT, A landmark study comparing MagicTouch SCB vs DES in Native Coronary Vessels

CLEVELAND, June 13, 2025 /PRNewswire/ -- Primary Investigator, Bernardo Cortese MD, proudly announces the successful completion of patient enrollment in the TRANSFORM II randomized...

AYR Provides Update on Delay of Q1 2025 Interim Financial Filings

MIAMI, June 13, 2025 (GLOBE NEWSWIRE) -- AYR Wellness Inc. (CSE: AYR.A, OTCQX: AYRWF) (“AYR” or the “Company”), a leading vertically integrated U.S. multi-state cannabis operator, announces that it has not completed the filing of its interim financial statements, management’s discussion and analysis, and related CEO and CFO certificates for the three-month period ended March 31, 2025 (collectively, the “Interim Filings”) by the previously anticipated date of June 13, 2025.‎

Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia at EHA 2025

New clinical results show sustained CRi, deep bone marrow responses, and encouraging survival in FLT3-mutant AML patients, including those previously treated with gilteritinib
New clinical results show sustained CRi, deep bone marrow responses, and encouraging survival in FLT3-mutant AML patients, including those previously treated with gilteritinib

Weekly Recap: 11 Health Press Releases You Need to See

A roundup of the most newsworthy healthcare press releases from PR Newswire this week, including advances in sleep apnea treatments, fall detection for seniors...

AI Ignites Digital Innovation: SUSE Summit China 2025 Opens in Beijing

The AI landscape is transforming at an unprecedented pace, unveiling new advances daily. However, enterprise-level AI innovation remains challenged by its complexity, as organizations...

BioArctic to initiate next cohorts in exidavnemab Phase 2a study after positive safety review

STOCKHOLM, June 13, 2025 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) announced today that the interim safety review of the clinical Phase...

Merry Life Launches Global Phase II Trial of TML-6, The First Drug Targeted at Autolysosome pathway for Therapy of Alzheimer’s Disease

TAINAN, June 12, 2025 /PRNewswire/ -- Merry Life Biomedical Company announces the launch of its global Phase II clinical trial for TML-6, a novel...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPatients